Lipocine Inc. (LPCN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
LPCN Chart
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.35 per share a year ago.
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Lipocine (LPCN) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.44 per share a year ago.
Lipocine Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kevin Roan Stempoint Capita LLP | 160,420 | $1.28M | $367,361.8 | -$914,394.19 | -71.34% |
 Christopher C. Powers Farther Finance Advisors, LLC | 1 | $7.99 | $2.23 | -$5.76 | -72.09% |
 Joshua Stipcich Tidemark, LLC | 59 | $188 | $135.11 | -$52.89 | -28.13% |
 BRIANNE SHERGILL Exome Asset Management LLC | 60,861 | $486,279 | $139,675.99 | -$346,603.01 | -71.28% |
 Zachary Canonico DIADEMA PARTNERS LP | 50,000 | $401,499.96 | $115,005 | -$286,494.96 | -71.36% |
Lipocine Inc. (LPCN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lipocine Inc. ever had a stock split?
Lipocine Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mahesh V. Patel CEO | NASDAQ (CM) Exchange | 53630X203 CUSIP |
| US Country | 14 Employees | - Last Dividend | 12 May 2023 Last Split | 22 Oct 2013 IPO Date |
Overview
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on the innovative research and development of drug delivery technologies, specifically targeting central nervous system (CNS) disorders. Established in 1997 and based in Salt Lake City, Utah, Lipocine Inc. strives to address the unmet needs in therapeutic areas through oral delivery solutions. The company is committed to enhancing patient convenience and compliance by developing formulations that improve upon the limitations of current treatment options.
Products and Services
TLANDO: Lipocine's lead product candidate, TLANDO, represents a significant advancement in testosterone replacement therapy (TRT). Formulated as an oral testosterone undecanoate, TLANDO is designed to restore normal testosterone levels in men with deficiencies, without the need for injections or topical applications.
TLANDO XR: Building on the foundation of TLANDO, TLANDO XR is an extended-release version aimed at offering once-daily dosing convenience. Having completed a Phase 2b clinical study, TLANDO XR reflects the company’s commitment to enhancing patient adherence and improving quality of life for those requiring TRT.
LPCN 1148: Lipocine is exploring the therapeutic potential of LPCN 1148, an oral prodrug of bioidentical testosterone tailored for patients with cirrhosis. Currently undergoing Phase 2 clinical studies, LPCN 1148 aims to provide a safer, more effective treatment option for this vulnerable patient population.
LPCN 1154: Targeting the treatment of postpartum depression, LPCN 1154 is an innovative oral neurosteroid therapy. Also in Phase 2 studies, it represents Lipocine’s commitment to addressing complex CNS disorders with novel oral drug delivery systems.
LPCN 2101: Specifically designed for women suffering from epilepsy, LPCN 2101 is a NAS candidate that further exemplifies Lipocine’s dedication to developing gender-specific therapies for CNS conditions.
LPCN 2203: For patients experiencing essential tremor, LPCN 2203 emerges as another key pipeline candidate, showcasing Lipocine’s ongoing efforts to expand its portfolio of CNS disorder treatments.
LPCN 1144: Lipocine has also developed LPCN 1144, an oral prodrug of bioidentical testosterone for individuals with pre-cirrhotic non-alcoholic steatohepatitis (NASH). Having completed Phase 2 testing, LPCN 1144 is a testament to the company's versatility in treating a range of conditions beyond CNS disorders.
LPCN 1107: Focused on the critical area of maternal health, LPCN 1107 is an oral iteration of 17-alpha-hydroxy progesterone caproate. Aimed at preventing recurrent preterm birth, this product candidate is currently under Phase 3 studies, illustrating Lipocine’s commitment to addressing significant women’s health issues through advanced drug delivery systems.
